[go: up one dir, main page]

AU5214200A - Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response - Google Patents

Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Info

Publication number
AU5214200A
AU5214200A AU52142/00A AU5214200A AU5214200A AU 5214200 A AU5214200 A AU 5214200A AU 52142/00 A AU52142/00 A AU 52142/00A AU 5214200 A AU5214200 A AU 5214200A AU 5214200 A AU5214200 A AU 5214200A
Authority
AU
Australia
Prior art keywords
sba
biocompatibility
stability
immune response
cellular immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52142/00A
Inventor
Nikolaus Grubhofer
Rainer Helmut Muller
Carsten Olbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasol GmbH
Original Assignee
Pharmasol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol GmbH filed Critical Pharmasol GmbH
Publication of AU5214200A publication Critical patent/AU5214200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU52142/00A 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response Abandoned AU5214200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Publications (1)

Publication Number Publication Date
AU5214200A true AU5214200A (en) 2000-12-12

Family

ID=7908697

Family Applications (2)

Application Number Title Priority Date Filing Date
AU52142/00A Abandoned AU5214200A (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
AU58091/00A Abandoned AU5809100A (en) 1999-05-20 2000-05-22 Stabilitats-, biokompatibilitats-optimiertes adjuvans (sba) zur erhohung der humoralen und zellularen immunantwort

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU58091/00A Abandoned AU5809100A (en) 1999-05-20 2000-05-22 Stabilitats-, biokompatibilitats-optimiertes adjuvans (sba) zur erhohung der humoralen und zellularen immunantwort

Country Status (11)

Country Link
EP (1) EP1183045A2 (en)
JP (1) JP2003500365A (en)
KR (1) KR20020012221A (en)
AU (2) AU5214200A (en)
BR (1) BR0010823A (en)
CA (1) CA2373239A1 (en)
DE (1) DE10024788A1 (en)
MX (1) MXPA01011660A (en)
TR (1) TR200103333T2 (en)
WO (2) WO2000071154A2 (en)
ZA (1) ZA200109147B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5214200A (en) * 1999-05-20 2000-12-12 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
SI1494732T1 (en) 2002-03-20 2008-08-31 Mannking Corp Inhalation apparatus
JP2007509164A (en) * 2003-10-23 2007-04-12 カイロン コーポレイション Stabilizing composition
FR2873386B1 (en) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa VACCINE COMPOSITION AGAINST RHODOCOCCUS EQUI
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
KR101486397B1 (en) 2005-09-14 2015-01-28 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
AU2007216966C1 (en) 2006-02-22 2014-03-20 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN109568740B (en) 2008-06-13 2022-05-27 曼金德公司 Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (en) 2008-06-20 2021-06-22 Mannkind Corp inhalation system
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Ultra-fast use of insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp Dry powder inhaler and composition therefor
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
CA2871641C (en) 2012-04-30 2016-12-13 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
ES2754388T3 (en) 2013-03-15 2020-04-17 Mannkind Corp Compositions and methods of microcrystalline dicetopiperazine
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3386540A1 (en) * 2015-12-08 2018-10-17 GlaxoSmithKline Biologicals S.A. Novel adjuvant formulations
KR102721917B1 (en) * 2022-05-31 2024-11-04 우리이앤엘 주식회사 Manufacturing method of liposomal vitamin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
JP2002521423A (en) * 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ Lipid emulsions and solid lipid microparticles as gene or drug carriers
AU5214200A (en) * 1999-05-20 2000-12-12 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Also Published As

Publication number Publication date
TR200103333T2 (en) 2002-04-22
JP2003500365A (en) 2003-01-07
WO2000071154A2 (en) 2000-11-30
ZA200109147B (en) 2002-05-08
MXPA01011660A (en) 2004-04-05
BR0010823A (en) 2002-03-05
KR20020012221A (en) 2002-02-15
WO2000071154A3 (en) 2001-06-28
AU5809100A (en) 2000-12-12
DE10024788A1 (en) 2000-11-23
CA2373239A1 (en) 2000-11-30
EP1183045A2 (en) 2002-03-06
WO2000071077A2 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
AU5214200A (en) Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
AU1080700A (en) Air cushion having support pin structure for shock-absorbing, method for manufacturing the air cushion, and footgear comprising the air cushion
AU2002258545A1 (en) Beverage brewing system
HUP0202885A3 (en) Vaccines
AU2001231204A1 (en) Genetically engineered tumor cell vaccines
AU6086300A (en) Recombinant envelope vaccine against flavivirus infection
AU2001258279A1 (en) Adjuvant for vaccines
AU1229101A (en) Cervical immobilization
AU6600300A (en) Pneumococcal vaccines
GB9901254D0 (en) Vaccines
AU5977700A (en) Vaccines
AU2003278175A1 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
AU1738201A (en) Adjuvants for nucleic acid vaccines
AU1600401A (en) Malaria vaccine
AU6158700A (en) Vaccine
AU2001247453A1 (en) Genetically stable cholera vaccines
AU2002236160A1 (en) Immunogenic complex comprising ribosomes
AU8604698A (en) Genetically engineered rhodococcus vaccine
AU2002254161A1 (en) M cell directed vaccines
AU4311600A (en) Cushion insole
AU4957800A (en) Vaccine against isa virus
MXPA01010701A (en) Vaccine.
AU7788600A (en) Colon-tumour-associated antigens
AU2002355913A1 (en) Anti-tumor vaccines
AU5084300A (en) New vaccine formulations - 1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase